Abstract: Objective This study aimed to summarize the clinical features and clinical outcomes of patients with anti-tumor drug-induced liver injury (DILI). Methods A total of 197 patients with anti-tumor DILI were encountered in this study between January and December 2024, and the clinical types were recorded. Clinical outcomes were observed after active liver protection treatment. Results Of the 197 patients with DILI, there were 26 cases of mixed type, 54 cases of cholestasis type and 117 cases of hepatocyte injury type; proportion of anorexia in hepatocyte injury type group was 47.9%, significantly higher than 25.9% in cholestasis type group or 25.0% in mixed type group (P<0.05); serum GGT and ALP levels in hepatocyte injury group were (241.6±79.3)U/L and (99.7±22.8)U/L, both much lower than [(835.2±274.8)U/L and (269.4±78.5)U/L, respectively, P＜0.05] in cholestasis type group or [(439.7±145.1)U/L and (203.2±66.9)U/L, respectively, P＜0.05] in mixed type group, while serum AST and ALT levels were (382.4±126.7)U/L and (601.9±183.5)U/L, both much higher than [(124.9±41.3)U/L and (109.8±32.7)U/L, respectively, P＜0.05] in cholestasis type group or [(140.5±46.2)U/L and (126.4±42.8)U/L, respectively, P＜0.05] in mixed type group; percentage of severe liver injury in patients with hepatocyte injury was 29.9%, much lower than 61.1% in patients with cholestasis type or 53.9% in those with mixed injury(P＜0.05); liver function tests returned to normal in 175 cases (88.8%) and didn’t in 22 cases (11.2%), and there were no significant differences among liver function recovery rates in the three groups(P＞0.05). Conclusion Anti-tumor immune, targeting and chemotherapy might induced DILI easily, and the hepatocyte injury type is very common. The prognosis is usually good with discontinuing anti-tumor medicines in time and active liver protecting treatment.

Key words: Drug-induced liver injury, Anti-tumor medicines, Clinical features, Outcome